


I hereby certify that this correspondence is being deposited with the United States Postal Service as express mail in an envelope addressed to:  
Director – U.S. Patent and Trademark Office, Washington, D.C. 20231 on this 21st day of December, 2001.

By

  
(Signature of person mailing)  
Janice M. Denison  
(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: **STEPHANIE K. HALL, ET AL:**

APPLICATION NO.: **TO BE ASSIGNED**

: Examiner: **TO BE ASSIGNED**

FILING DATE: **HEREWITH**

: Group Art Unit: **TO BE ASSIGNED**

TITLE: **METHODS AND REAGENTS FOR  
DETECTING INCREASED RISK OF  
DEVELOPING AN INFLAMMATORY  
DISORDER**

:


Director – U.S. Patent and Trademark Office  
Washington, D.C. 20231

STATEMENT REGARDING SUBMISSION  
OF SEQUENCE LISTING UNDER 37 C.F.R. §1.821(f)

I hereby state that the information recorded in computer readable form is identical to  
the written sequence listing.

Respectfully submitted,

Date: 12/21/01

  
Jennifer A. Kispert  
Attorney for Applicant(s)  
Reg. No. 40,049

Pfizer Inc.  
Patent Department, MS 4159  
Eastern Point Road  
Groton, Connecticut 06340  
(860) 715-5747

EXPRESS MAIL NO. FL911725504US

10032244-122101